Next Article in Journal
Placenta-Derived Mesenchymal Stem Cells (pMSCs) Reverse Diabetes-Associated Endothelial Complications in a Preclinical Animal Model
Previous Article in Journal
Cannabigerol Attenuates Memory Impairments, Neurodegeneration, and Neuroinflammation Caused by Transient Global Cerebral Ischemia in Mice
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Genome-Wide mRNA and lncRNA Expression Profiling to Uncover Their Role in the Molecular Pathogenesis of Developmental Dysplasia of the Hip

1
Dr. Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital, Department of Orthopaedics and Traumatology, Demetevler, Vatan Cd., Yenimahalle, Ankara 06200, Türkiye
2
Department of Biology, Faculty of Science, Gazi University, Ankara 06560, Türkiye
*
Author to whom correspondence should be addressed.
Int. J. Mol. Sci. 2025, 26(16), 8058; https://doi.org/10.3390/ijms26168058 (registering DOI)
Submission received: 15 July 2025 / Revised: 11 August 2025 / Accepted: 14 August 2025 / Published: 20 August 2025
(This article belongs to the Section Molecular Genetics and Genomics)

Abstract

Developmental dysplasia of the hip (DDH) is a congenital disorder influenced by genetic and epigenetic factors. This study aimed to elucidate the molecular pathogenesis of DDH through a comprehensive transcriptomic analysis, identifying differentially expressed genes (DEGs) and long non-coding RNAs (lncRNAs) in hip joint capsules from DDH patients and healthy controls. RNA sequencing data from 12 samples (6 DDH, 6 controls) were retrieved from the NCBI database. Functional annotation was performed using Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analyses via the DAVID tool. A protein–protein interaction (PPI) network of DEGs was constructed using STRING with medium confidence settings. Among 78,930 transcripts, 4.3% were significantly differentially expressed, according to DESeq2 analysis. A total of 3425 DEGs were identified (FDR < 0.05, |log2 FC| > 2), including 1008 upregulated and 2417 downregulated transcripts in DDH samples. Additionally, 1656 lncRNAs were detected among the DEGs. These findings enhance our understanding of the genetic and epigenetic landscape of DDH and highlight the involvement of key biological pathways such as cell cycle regulation and Wnt signaling. This study provides a foundation for future molecular research into the pathogenesis of DDH.

1. Introduction

DDH refers to a spectrum of abnormalities affecting the hip joint, ranging from mild acetabular dysplasia to subluxation and complete dislocation of the hip [1]. The incidence of DDH varies significantly depending on geographic region and ethnic groups, ranging from 0.06 to 76.1 per 1000 live births [2]. DDH has a complex etiology, and its pathogenesis is not yet fully understood. It is considered a multifactorial disorder involving a combination of genetic, environmental, and mechanical factors [3]. Several risk factors have been identified for DDH, including breech presentation, female sex, first-born status, positive family history, high birth weight, foot deformities, multiple gestation, and oligohydramnios [2,3].
Despite ongoing research into the genetic pathogenesis of developmental dysplasia of the hip, the precise genetic mechanisms underlying the disease remain incompletely understood [3,4,5,6,7]. Several genes have been reported to show a strong correlation with DDH, including GDF5, HOXB9, HOXD9, PAPPA2, COL1A1, ASPN, CX3CR1, UQCC, POLE, TBX4, MMP24, and NOTCH2 [3,4,5,8,9]. Although these genetic variations have been found to be associated with DDH, their exact impact on disease development remains unclear, and no gene has been definitively identified as being causally linked to the pathogenesis of DDH [3,4,6]. Due to the genetic uncertainty surrounding DDH, gene expression analyses have been conducted to gain new insights into the underlying molecular mechanisms. These studies have identified numerous genes that are differentially expressed and potentially involved in the pathogenesis of DDH [10]. Recently, the role of epigenetic mechanisms—known to be involved in various biological processes—has also been investigated. Findings have shown that both transcriptional and epigenetic regulations may serve as potential modulatory mechanisms in DDH, providing new clues toward understanding its molecular basis [7,11]. On the other hand, there is still a meager number of studies in this field, both at the genome-wide gene expression level and from an epigenetic perspective. A review of the literature shows that, to the best of our knowledge, only a single transcriptome-level (RNA-seq) study has been conducted on Homo sapiens to investigate the pathophysiology of DDH [10].
With the advancement of next-generation sequencing technologies, the discovery of various non-coding RNA types, such as lncRNA, has marked significant progress in the field of molecular biology. LncRNAs, a class of non-coding RNAs with more than 200 nucleotides, do not have protein-coding potential but play crucial roles in maintaining cellular homeostasis. They are involved in regulating gene expression at the epigenetic, transcriptional, and post-transcriptional levels, and play key roles in various biological processes such as somatic cell reprogramming and the pluripotency of stem cells [12,13]. Recent studies have shown that there are more than 100,000 distinct lncRNAs encoded by the human genome [14,15]. The expression of lncRNAs has been associated with a range of diseases, including cancer and neurological disorders, highlighting their significance as key factors in both normal and pathological conditions [12,13,15,16]. In recent years, evidence has emerged suggesting that lncRNAs play a crucial role in the proliferation and differentiation of osteoblasts and chondrocytes [17,18,19].
LncRNAs have been shown to regulate gene expression, playing a significant role in osteogenic differentiation and bone regeneration. In particular, LncRNA H19 has been found to play a vital role in osteogenic induction [19]. As the effects of lncRNAs on the skeletal system have become more evident, studies investigating the relationship between DDH and lncRNAs at the genomic level have emerged. These studies have begun to reveal promising data regarding the epigenetic mechanisms underlying DDH [20,21].
To the best of our knowledge, this study is the first to investigate the molecular pathogenesis of DDH by using genome-wide transcript and lncRNA profiling. In this study, transcriptomic libraries available in the database were analyzed using various bioinformatics tools to identify transcripts and lncRNAs as epigenetic regulators which are involved in the pathogenesis of DDH. Both transcripts and lncRNAs were identified, and their potential roles in DDH development were discussed.

2. Results

2.1. Mapping Efficiency

To ensure the reliability of the in silico RNA-seq analysis, standard quality control thresholds were applied. Raw reads were subjected to adapter trimming and low-quality base removal, and FastQC reports confirmed high per-base sequence quality (Q ≥ 30), low adapter contamination, and appropriate GC content. Alignment to the Ensemble reference human genome GRCh38 was performed using HISAT2, with an average overall mapping rate exceeding 88%. The proportion of reads that mapped to the Ensemble reference genes ranged from 81 to 98% for the 12 samples (Table 1).

2.2. Differentially Expressed Genes in Hip Joint Capsules of DDH Patients

After mapping, 78,930 transcripts were identified. The read counts of 78,930 transcripts were calculated to normalize the expression level of the transcripts. Using DESeq2 with a paired analysis design, 4.3% of all genes were identified as significantly differentially expressed, demonstrating a substantial number of gene expression differences between the DDH patients and control groups. A total of 3425 DEGs were identified between DDH vs. the control samples based on the selection criteria (a false discovery rate < 0.05 and |log2 FC| > 2) (Table S1).
The differential expression analysis of the transcripts between the samples revealed that most of the transcripts exhibited downregulation in DDH patients compared with the controls. It was found that 1008 transcripts were upregulated, while 2417 transcripts were downregulated in DDH patients. Figure 1 presents a volcano plot to examine the difference in the expression level of genes in two groups of samples and the statistical significance of the differences. Moreover, the top 50 up- and downregulated genes are listed in Table 2.
The plotMA function of DESeq2 was applied to obtain the log2 attribution to the given variables over the mean of normalized counts for an experiment with a two-group comparison (Figure 2).

2.3. Functional Enrichment Analysis of DEGs

DEGs identified between the DDH and control samples were analyzed using GO term enrichment to investigate their functions (Figure 3). The transcripts were classified on the basis of molecular function (MF), biological process (BP), and cellular component (CC) ontology terms.
A list of 345 biological process GO terms and 41 pathways were retrieved. DEGs are mainly involved in signal transduction following immune response and cell adhesion. Several transcripts were assigned to GO CC terms, and the top three CC terms are plasma membrane, membrane, and extracellular region. The most enriched MF term is calcium ion binding.
Pathway enrichment analysis using the KEGG database was also performed to reveal the active biological pathways involved in DDH patients compared with healthy individuals. KEGG pathway analysis revealed that the cytokine–cytokine receptor interaction pathway is the most abundant pathway.
DEGs were also subjected to STRING analysis to investigate the PPI. K-means clustering was applied, and the top network in the control and DDH groups are presented in Figure 4.
Cell communication was found to be one of the top 10 most common biological processes, while the cytokine–cytokine receptor interaction pathway was found to be one of the most significant pathways. The descriptions of the clusters are listed in Table 3.

2.4. Identification of Long Non-Coding RNAs

Since the long-noncoding RNAs have various functions, in order to analyze the contribution of m-lncRNAs to DDH, they were also identified in the study. A total of 1656 lncRNAs were determined among the DEGs (Table S2). Moreover, the top 100 up- and downregulated lncRNAs are listed in Table 4. The presence of a large number of lncRNAs among the DEGs demonstrated that they have important roles in DDH disease.

3. Discussion

In this study, bioinformatic analyses were conducted to elucidate the genetic and epigenetic mechanisms of DDH. One of the most striking findings of the study was the identification of 3425 differentially expressed genes in DDH, with 1008 being upregulated and 2417 downregulated. Additionally, Gene Ontology and KEGG pathway analyses revealed that the regulation of various signaling pathways is implicated in the molecular pathogenesis of DDH. Another significant finding was the observation of significant expression changes in 1656 lncRNAs in DDH, with 433 lncRNAs showing increased expression and 1223 lncRNAs showing decreased expression.
In the present study, it was found that the expression of Matrix Metalloproteinase13 (MMP13) and Matrix Metalloproteinase3 (MMP3) was reduced in the hip joint capsule of patients with DDH. Similarly, a transcriptomic study conducted in 2021 reported decreased expression of MMP1, MMP3, MMP9, and MMP13 in the joint capsule of DDH patients, which is consistent with the findings of our study [10]. However, these results are intriguingly different from studies showing increased expression of MMP13 and MMP3 in the cartilage of DDH patients [21,22]. In a study investigating biomarkers of cartilage degeneration in DDH, an increase in MMP13 expression in the joint cartilage matrix of DDH patients was found, and it was revealed that cartilage degeneration progresses in these patients [23]. The effects of MMP13 and MMP3, members of the matrix metalloproteinase family, on cartilage degeneration are also supported by other studies [21,22]. A study on human osteoarthritic cartilage reported that MMP expression in chondrocytes varies according to the depth of chondrocytes in the cartilage and the severity of the disease [24]. Histological differences between capsule and cartilage tissues suggest that MMP expression may play tissue-specific roles. Additionally, as shown in osteoarthritis patients, the stage of DDH may also influence MMP expression. This situation may be the main reason for the conflicting results regarding MMP expression between capsule and cartilage tissues reported in the literature.
The Growth Differentiation Factor 5 (GDF5) gene has been identified as an important candidate gene associated with DDH in numerous studies [3,8,9,25]. It has been shown that GDF5 plays a critical role in joint and bone formation and supports the condensation of mesenchymal cells [8,25]. Reduced GDF5 expression has been suggested to impair the condensation of these cells and chondrogenic differentiation, potentially leading to a decrease in the number of chondrogenic cells in the hip joint [25]. A study investigating the effects of GDF5 stimulation on chondrocytes demonstrated that GDF5 stimulation had an inhibitory effect on the expression of catabolic genes and a stimulatory effect on the expression of anabolic genes in human articular chondrocytes. It was shown that GDF5 stimulation inhibits the canonical Wnt signaling pathway via DKK1 (Dickkopf WNT signaling pathway inhibitor 1), thereby reducing Wnt-induced MMP13 expression and preventing its catabolic effects on chondrocytes. Furthermore, when DKK1 was inhibited, there was a subsequent increase in MMP13 expression, which was associated with an increase in chondrocyte apoptosis [26]. Conversely, some studies have reported that DKK1 stimulation increases chondrocyte apoptosis and cartilage degradation [27,28]. In conclusion, all these findings suggest that DKK1 plays a regulatory role in chondrocyte homeostasis.
The DKK1 gene has been identified as a candidate gene associated with DDH in several studies [3,4,8]. In the present study, it is noteworthy that the expression of an lncRNA (lncRNA activating regulator of DKK1), which has a regulatory effect on the DKK1 gene, was found to be reduced. This finding supports our hypothesis that lncRNAs may play a role in the epigenetic mechanisms of DDH. The Wnt Inhibitor Factor 1 (WIF1) gene inhibits the WNT signaling pathway, which plays a crucial role in embryonic bone and joint development. The relationship between this gene and DDH was first demonstrated in a study conducted in the Chinese population in 2019. According to the results of that study, it was found that the expression of the WIF1 gene was significantly increased in the joint capsule and ligaments of DDH patients [29]. In our study, we also found that the expression of the WIF1 gene was increased in the DDH joint capsule. In this context, our study confirms the relationship between WIF1 and DDH. The study conducted in the Chinese population suggested that the excessive expression of WIF1 in DDH patients could be associated with the reshaping of the hip’s macro-morphology through the suppression of Wnt signaling [29]. In contrast to previous studies, our research found that genes regulating the inhibition of Wnt signaling pathways, or lncRNAs that regulate these genes, were affected in the opposite direction. While the increase in WIF1 gene expression contributes to the inhibition of Wnt signaling, the decreased expression of “lncRNA activating regulator of DKK1”, the transcriptional activator of DKK1, may lead to a reduction in DKK1 levels and consequently a decrease in the inhibition of the Wnt signaling pathway. These findings suggest that both excessive activation and inhibition of the Wnt signaling pathway may play a role in the development of DDH. More comprehensive functional studies are needed to fully understand the impact of the Wnt signaling pathway on DDH’s pathogenesis.
It is well known that Wnt signaling cascades play a role in the development of cartilage, bone, muscle, and joints [30]. Although alterations in Wnt signaling have been reported to adversely affect chondrocyte differentiation and endochondral ossification, its exact role in joint development remains unclear. There are contradictions among reports in the literature, as Wnt’s ligand expression, target cells, and signaling pathways are complex [31]. In our study, the conclusion that Wnt signaling pathways may be affected differently can be explained by the fact that these pathways are in complex interactions with numerous regulators. Additionally, it has been shown that the Wnt signaling pathway is one of the affected candidate pathways in DDH [7]. The fact that genes with regulatory effects on the Wnt signaling pathway, such as DKK1, FRZB, and WISP3, have also been identified as candidate genes for DDH further supports the potential role of this signaling pathway in the pathogenesis of DDH [8].
The Wnt signaling pathway is negatively regulated by various soluble factors, such as WIF1 and DKK, in the extracellular environment [29]. In our study, it was found that both of these genes, which are influential in the Wnt signaling pathway, were affected in patients with DDH. Additionally, the results of the GO analysis revealed that the most affected biological process was signal transduction, the molecular functions were calcium ion binding and signaling receptor binding, and among the top 10 affected cellular components, the extracellular region, extracellular space, and extracellular matrix were identified. These findings suggest that extracellular matrix-dependent signaling mechanisms and the extracellular microenvironment may play important biological roles in the pathogenesis of DDH. In the literature, calcium ion binding is well known to play a critical role in both bone remodeling and growth, as well as in intracellular signal transduction. Ca2+ is involved in a wide range of cellular processes such as mitosis, neuronal transmission, gene transcription, and cell death, and it plays a particularly important role in the regulation of gene expression. In osteoblasts, calcium-mediated signaling pathways are among the key mechanisms regulating cell proliferation and differentiation [32]. Similarly, Ca2+ signaling in osteoclasts is essential for various cellular functions, including differentiation, bone resorption, and gene transcription. Recent studies have highlighted the importance of intracellular Ca2+ signaling for osteoclast differentiation and shown that this process initiates osteoclast-specific gene transcription to promote differentiation [33]. Additionally, in cells of the osteoblastic lineage, Ca2+ signals, taken up via calcium channels in response to both mechanical and hormonal stimuli, affect gene expression and cellular behavior, thereby contributing to bone homeostasis. Calcium signaling, which regulates the interaction between osteoblasts and osteoclasts, also plays a critical role in the modulation of bone remodeling. These signals are associated with the activation of intracellular signaling pathways that control cell behavior and phenotype, including gene expression patterns [34]. In this context, the finding that “calcium ion binding” was among the most affected molecular functions in our study of DDH cases suggests that calcium signaling and/or calcium-dependent cellular processes may be impaired in this disease.
Cytokines and cytokine receptors are important proteins involved in a wide range of physiological processes such as mediating cellular communication, initiating and regulating inflammation, and controlling cell proliferation, differentiation, and apoptosis. The effects of cytokines such as IL-1β, IL-6, TNF-α, and TGF-β on the skeletal system are known [7,10,19,35]. For example, TGF-β signaling has been shown to play an important role in embryonic skeletal development as well as postnatal bone and cartilage homeostasis [35]. Additionally, in the hip joint capsule of patients with DDH, TGF-β1 has been reported to be downregulated while TGF-β2 is upregulated [10]. In our study, one of the most enriched pathways in the KEGG analysis was the “cytokine–cytokine receptor interaction” pathway. These findings suggest that alterations in cytokine signaling pathways may play a role in the pathogenesis of DDH.
Previous studies have reported that Myocilin (MYOC), a gene known to be associated with glaucoma, functions as a modulator of the Wnt signaling pathway [36,37]. In the present study, an increase in the expression of 1,008 transcripts was observed, with MYOC being the gene showing the most significant increase. Given the modulatory effect of MYOC on the Wnt signaling pathway, it is likely to be associated with the pathogenesis of DDH. This is the first study to demonstrate a relationship between the MYOC gene and DDH.
Iroquois Homeobox (IRX) genes belong to the homeobox family and encode homeobox proteins. Irx genes play crucial roles in regulating various developmental processes, particularly during embryonic development, where they are involved in cell specification, cell differentiation, and the organization of body structures [38]. Additionally, a study conducted in 2010 demonstrated that IRX3 is transcriptionally induced by the Wnt signaling pathway during neurulation [39]. In this study, the expression of the IRX1 gene was found to be the fifth most increased among the genes in DDH patients. The significantly increased expression of this gene in DDH patients suggests that it may play a critical role during the embryonic development of the hip joint and could potentially be a direct or indirect regulatory gene in the pathogenesis of DDH.
It is known that lncRNA-H19 has an effect on osteogenic and chondrogenic differentiation [19,40]. There are only two studies investigating the role of lncRNAs in the epigenetic mechanisms of DDH pathogenesis. These studies have particularly focused on the effects of lncRNA-H19 on chondrocytes, showing that H19 could be an important epigenetic regulatory factor in the development of DDH [20,21]. Recent studies have shown an increasing amount of data indicating that lncRNAs play a significant role in various diseases [13,16]. Based on the hypothesis that a greater number of lncRNAs may be involved in the epigenetic regulatory mechanisms of DDH, our analysis revealed changes in the expression of numerous lncRNAs.
Particularly, the interactions of some of these lncRNAs with target genes are noteworthy. For example, the AFF3 gene regulates the expression of genes involved in mesoderm and ectoderm development, mesenchymal cell proliferation, cell adhesion, angiogenesis, and cartilage and lens development [41]. In our study, the increased expression of the lncRNA ENSG00000301580, which has an antisense effect on AFF3, suggests that this gene may play a regulatory role in the pathogenesis of DDH. Another lncRNA, ENSG00000286411, which also shows increased expression in DDH, exerts an antisense effect on Cyclin-dependent kinase (CDK) 14. CDK14, as a cell cycle-dependent protein kinase, is involved in the canonical Wnt/β-catenin signaling pathway, which directs the cell cycle towards mitosis. It has been reported that the suppression of CDK14 leads to proliferative and migratory defects in human umbilical cord endothelial and epithelial cells [42]. Similarly, in the hip joint, the proliferation, differentiation, and migration of mesenchymal cells are crucial during development. The increased expression of the lncRNA ENSG00000286411, which targets CDK14 in DDH, may contribute to the disruption of these mechanisms. In a transcriptomic study, it was found that the CDK1 protein, which is essential for the progression of mitosis, is downregulated in DDH patients [10]. This finding aligns with the results we obtained in our study, where the lncRNA ENSG00000286411 targeting CDK14 showed increased expression in DDH. In both studies, it has been demonstrated that the regulation of CDK family members, which play a role in the mitotic phase of the cell cycle, is disrupted in association with DDH.
The transcriptomic data used in our study were obtained from a publicly available dataset (SRX10431608 through SRX10431613). The dataset includes six patient and six control samples. While this number is limited, it is a common feature in early-stage or pioneering studies utilizing publicly available transcriptomic data.
It should be acknowledged that the differential expression of the identified genes does not necessarily imply a causal role in the pathology of DDH. While some DEGs may act as upstream drivers contributing to disease initiation or progression, others may represent downstream, secondary alterations arising from pathological processes initiated elsewhere. This distinction is particularly important in complex biological systems, where feedback loops and compensatory mechanisms can obscure the temporal sequence of molecular events. We should emphasize that resolving these relationships will require further functional validation studies, ideally complemented by analyses including time-course experiments, functional perturbation studies, single-cell trajectory analyses, and integration with genetic and clinical data, which may help determine whether the observed differential expression reflects a causal role in the pathology or a secondary consequence of upstream events.
On the other hand, while experimental validation is generally needed to confirm computational findings, it is not an absolute prerequisite for the contribution of in silico studies to the scientific literature. It is important to note that in silico analyses provide a valuable framework, especially in emerging or resource-limited research areas, and yield valuable insights and contribute meaningfully to the scientific literature even without direct experimental validation. Due to logistical and infrastructural constraints, we were unable to perform wet-lab validation in the present study. However, this limitation does not negate the significance of these computational results, which are based on well-established bioinformatic pipelines and stringent statistical criteria. Moreover, given that this study is among the first to explore this specific biological context, our findings serve as an initial resource to guide future experimental work. It is widely recognized that computational predictions must be interpreted with caution, yet they often reveal novel candidates and hypotheses that cannot be uncovered without such analyses.
Functional interpretation of differentially expressed lncRNAs remains challenging due to limited annotation and the lack of experimentally validated target interactions in the current databases. As a result, constructing a comprehensive regulatory network was not feasible within the scope of this study. Future research incorporating experimental validation and expanded lncRNA databases will be essential to elucidate the biological roles of these molecules.

4. Materials and Methods

4.1. Data Acquisition

The raw Illumina RNA sequencing data of 12 samples were retrieved from the NCBI databank. The data were obtained from six hip joint capsules of patients with DDH (SRX10431608–SRX10431613) and six hip joint capsules of control subjects (SRX10431614–SRX10431619).

4.2. Transcript Data Analysis

After filtering out low-quality reads (Phred score cutoff: 20) with TrimGalore (https://github.com/FelixKrueger/TrimGalore) (accessed on 2 June 2025), Hisat2 was used to map quality-filtered reads to a reference human genome (hg38) [43]. The aligned read files were further processed by the FeatureCounts program of the SubRead package to obtain read counts [44]. Differential expression analyses were performed using DeSeq2 [45]. DEGs were identified and filtered with the following criteria: false discovery rate < 0.05 and |log2 FC| > 2. The Bioconductor BiomaRt R package (version 4.5) was used for lncRNA annotation [46].

4.3. Functional Enrichment Analysis

The GO terms and KEGG pathway analysis pathways were discovered as functional annotation categories using the DAVID web-based functional annotation tool [47]. To identify the interactions of DEGs, a PPI network was constructed using STRING (https://string-db.org/) with a “minimum required interaction score” set to medium confidence (0.400). An extensive literature survey was performed to uncover the roles of DEGs in DDH.

5. Conclusions

This study is one of the first comprehensive transcriptomic analyses conducted to illuminate the molecular pathogenesis of developmental dysplasia of the hip, identifying various genes with differential expression in the hip joint capsules between healthy controls and DDH patients. The findings from our study suggest that not only protein-coding genes but also lncRNAs may play a significant role in the epigenetic mechanisms underlying DDH’s pathogenesis. Our work provides valuable data that could guide future molecular biological research aimed at understanding the genetic and epigenetic basis of DDH.

Supplementary Materials

The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/ijms26168058/s1.

Author Contributions

İ.K.: Conception, writing—original draft. M.T.: Formal analysis, methodology, supervision, data curation. S.Y.: Writing—review and editing, methodology. R.B.: Writing—review and editing, methodology, visualization. All authors agree to and support the work presented herein. All authors have read and agreed to the published version of the manuscript.

Funding

The authors did not receive support from any organization for the submitted work.

Institutional Review Board Statement

Not applicable.

Data Availability Statement

The datasets analyzed during the current study are available in the NCBI database, accession numbers SRX10431608–SRX10431613 and SRX10431614–SRX10431619.

Acknowledgments

All authors have made appropriate contributions to the conception and design of the study.

Conflicts of Interest

The authors declare no conflict of interest.

Abbreviations

DDHDevelopmental dysplasia of the hip
LncRNALong non-coding RNA
GOGene Ontology
KEGGKyoto Encyclopedia of Genes and Genomes
DEGsDifferentially expressed genes
MFMolecular function
BPBiological process
CCCellular component
MMP13Matrix Metalloproteinase 13
MMP3Matrix Metalloproteinase 3
GDF5Growth Differentiation Factor 5
DKK1Dickkopf WNT Signaling Pathway Inhibitor 1
WIF1Wnt Inhibitor Factor 1
MYOCMyocilin
IRXIroquois Homeobox

References

  1. Pollet, V.; Percy, V.; Prior, H.J. Relative risk and incidence for developmental dysplasia of the hip. J. Pediatr. 2017, 181, 202–207. [Google Scholar] [CrossRef]
  2. Loder, R.T.; Skopelja, E.N. The epidemiology and demographics of hip dysplasia. ISRN Orthop. 2011, 2011, 238607. [Google Scholar] [CrossRef] [PubMed]
  3. Kenanidis, E.; Gkekas, N.K.; Karasmani, A.; Anagnostis, P.; Christofilopoulos, P.; Tsiridis, E. Genetic predisposition to developmental dysplasia of the hip. J. Arthroplast. 2020, 35, 291–300.e1. [Google Scholar] [CrossRef] [PubMed]
  4. Yang, W.; Jin, G.; Qian, K.; Zhang, C.; Zhi, W.; Yang, D.; Lu, Y.; Han, J. Comprehensive bioinformatics analysis of susceptibility genes for developmental dysplasia of the hip. Intractable Rare Dis. Res. 2022, 11, 70–80. [Google Scholar] [CrossRef] [PubMed]
  5. Jacobsen, K.K.; Laborie, L.B.; Kristiansen, H.; Schäfer, A.; Gundersen, T.; Zayats, T.; Rosendahl, K. Genetics of hip dysplasia—A systematic literature review. BMC Musculoskelet. Disord. 2024, 25, 762. [Google Scholar] [CrossRef]
  6. Wen, J.; Ping, H.; Kong, X.; Chai, W. Developmental dysplasia of the hip: A systematic review of susceptibility genes and epigenetics. Gene 2023, 853, 147067. [Google Scholar] [CrossRef]
  7. Cheng, B.; Jia, Y.; Wen, Y.; Hou, W.; Xu, K.; Liang, C.; Cheng, S.; Liu, L.; Chu, X.; Ye, J.; et al. Integrative analysis of microRNA and mRNA sequencing data identifies novel candidate genes and pathways for developmental dysplasia of hip. Cartilage 2021, 13, 1618S–1626S. [Google Scholar] [CrossRef]
  8. Harsanyi, S.; Zamborsky, R.; Kokavec, M.; Danisovic, L. Genetics of developmental dysplasia of the hip. Eur. J. Med. Genet. 2020, 63, 103990. [Google Scholar] [CrossRef]
  9. Gkiatas, I.; Boptsi, A.; Tserga, D.; Gelalis, I.; Kosmas, D.; Pakos, E. Developmental dysplasia of the hip: A systematic literature review of the genes related with its occurrence. EFORT Open Rev. 2019, 4, 595–601. [Google Scholar] [CrossRef]
  10. Li, C.; Peng, Z.; Zhou, Y.; Su, Y.; Bu, P.; Meng, X.; Li, B.; Xu, Y. Comprehensive analysis of pathological changes in hip joint capsule of patients with developmental dysplasia of the hip. Bone Jt. Res. 2021, 10, 558–570. [Google Scholar] [CrossRef]
  11. Liu, J.; Bao, Y.; Fan, J.; Chen, W.; Shu, Q. Microstructure changes and miRNA–mRNA network in a developmental dysplasia of the hip rat model. iScience 2024, 27, 109449. [Google Scholar] [CrossRef]
  12. Chen, L.-L.; Carmichael, G.G. Long noncoding RNAs in mammalian cells: What, where, and why? Wiley Interdiscip. Rev. RNA 2010, 1, 2–21. [Google Scholar] [CrossRef]
  13. Mishra, S.; Verma, S.S.; Rai, V.; Awasthee, N.; Chava, S.; Hui, K.M.; Kumar, A.P.; Challagundla, K.B.; Sethi, G.; Gupta, S.C. Long non-coding RNAs are emerging targets of phytochemicals for cancer and other chronic diseases. Cell Mol. Life Sci. 2019, 76, 1947–1966. [Google Scholar] [CrossRef]
  14. Uszczynska-Ratajczak, B.; Lagarde, J.; Frankish, A.; Guigó, R.; Johnson, R. Towards a complete map of the human long non-coding RNA transcriptome. Nat. Rev. Genet. 2018, 19, 535–548. [Google Scholar] [CrossRef]
  15. Fang, S.; Zhang, L.; Guo, J.; Niu, Y.; Wu, Y.; Li, H.; Zhao, L.; Li, X.; Teng, X.; Sun, X.; et al. NONCODEV5: A comprehensive annotation database for long non-coding RNAs. Nucleic Acids Res. 2018, 46, D308–D314. [Google Scholar] [CrossRef]
  16. Chen, G.; Wang, Z.; Wang, D.; Qiu, C.; Liu, M.; Chen, X.; Zhang, Q.; Yan, G.; Cui, Q. LncRNADisease: A database for long-non-coding RNA-associated diseases. Nucleic Acids Res. 2013, 41, D983–D986. [Google Scholar] [CrossRef]
  17. Zhang, G.; Wu, Y.; Xu, D.; Yan, X. Long noncoding RNA UFC1 promotes proliferation of chondrocyte in osteoarthritis by acting as a sponge for miR-34a. DNA Cell Biol. 2016, 35, 691–695. [Google Scholar] [CrossRef] [PubMed]
  18. Yang, Q.; Jia, L.; Li, X.; Guo, R.; Huang, Y.; Zheng, Y.; Li, W. Long noncoding RNAs: New players in the osteogenic differentiation of bone marrow- and adipose-derived mesenchymal stem cells. Stem Cell Rev. Rep. 2018, 14, 297–308. [Google Scholar] [CrossRef] [PubMed]
  19. Zhou, Z.; Hossain, M.S.; Liu, D. Involvement of the long noncoding RNA H19 in osteogenic differentiation and bone regeneration. Stem Cell Res. Ther. 2021, 12, 74. [Google Scholar] [CrossRef]
  20. Ning, B.; Jin, R.; Wang, D.; Sun, J. The H19/let-7 feedback loop contributes to developmental dysplasia and dislocation of the hip. Physiol. Res. 2019, 68, 275–284. [Google Scholar] [CrossRef] [PubMed]
  21. Wang, C.-L.; Zuo, B.; Li, D.; Zhu, J.-F.; Xiao, F.; Zhang, X.-L.; Chen, X.-D. The long noncoding RNA H19 attenuates force-driven cartilage degeneration via miR-483-5p/Dusp5. Biochem. Biophys. Res. Commun. 2020, 529, 210–217. [Google Scholar] [CrossRef] [PubMed]
  22. Kim, D.; Paggi, J.M.; Park, C.; Bennett, C.; Salzberg, S.L. Graph-based genome alignment and genotyping with HISAT2 and HISAT-genotype. Nat. Biotechnol. 2019, 37, 907–915. [Google Scholar] [CrossRef] [PubMed]
  23. Liao, Y.; Smyth, G.K.; Shi, W. featureCounts: An efficient general purpose program for assigning sequence reads to genomic features. Bioinformatics 2014, 30, 923–930. [Google Scholar] [CrossRef]
  24. Love, M.I.; Huber, W.; Anders, S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 2014, 15, 550. [Google Scholar] [CrossRef]
  25. Durinck, S.; Spellman, P.T.; Birney, E.; Huber, W. Mapping identifiers for the integration of genomic datasets with the R/Bioconductor package biomaRt. Nat. Protoc. 2009, 4, 1184–1191. [Google Scholar] [CrossRef]
  26. Sherman, B.T.; Hao, M.; Qiu, J.; Jiao, X.; Baseler, M.W.; Lane, H.C.; Imamichi, T.; Chang, W. DAVID: A web server for functional enrichment analysis and functional annotation of gene lists (2021 update). Nucleic Acids Res. 2022, 50, W216–W221. [Google Scholar] [CrossRef]
  27. Ning, B.; Sun, J.; Yuan, Y.; Yao, J.; Wang, P.; Ma, R. Early articular cartilage degeneration in a developmental dislocation of the hip model results from activation of β-catenin. Int. J. Clin. Exp. Pathol. 2014, 7, 1369–1378. [Google Scholar] [PubMed]
  28. Feng, W.-J.; Wang, H.; Shen, C.; Zhu, J.-F.; Chen, X.-D. Severe cartilage degeneration in patients with developmental dysplasia of the hip. IUBMB Life 2017, 69, 179–187. [Google Scholar] [CrossRef]
  29. Freemont, A.J.; Hampson, V.; Tilman, R.; Goupille, P.; Taiwo, Y.; Hoyland, J.A. Gene expression of matrix metalloproteinases 1, 3, and 9 by chondrocytes in osteoarthritic human knee articular cartilage is zone and grade specific. Ann. Rheum. Dis. 1997, 56, 542–549. [Google Scholar] [CrossRef]
  30. Dai, J.; Shi, D.; Zhu, P.; Qin, J.; Ni, H.; Xu, Y.; Yao, C.; Zhu, L.; Zhu, H.; Zhao, B.; et al. Association of a single nucleotide polymorphism in growth differentiate factor 5 with congenital dysplasia of the hip: A case-control study. Arthritis Res. Ther. 2008, 10, R126. [Google Scholar] [CrossRef]
  31. Enochson, L.; Stenberg, J.; Brittberg, M.; Lindahl, A. GDF5 reduces MMP13 expression in human chondrocytes via DKK1 mediated canonical Wnt signaling inhibition. Osteoarthr. Cartil. 2014, 22, 566–577. [Google Scholar] [CrossRef]
  32. Weng, L.-H.; Ko, J.-Y.; Wang, C.-J.; Sun, Y.-C.; Wang, F.-S. Dkk-1 promotes angiogenic responses and cartilage matrix proteinase secretion in synovial fibroblasts from osteoarthritic joints. Arthritis Rheum. 2012, 64, 3267–3277. [Google Scholar] [CrossRef]
  33. Weng, L.-H.; Wang, C.-J.; Ko, J.-Y.; Sun, Y.-C.; Wang, F.-S. Control of Dkk-1 ameliorates chondrocyte apoptosis, cartilage destruction, and subchondral bone deterioration in osteoarthritic knees. Arthritis Rheum. 2010, 62, 1393–1402. [Google Scholar] [CrossRef]
  34. Sun, Y.; You, Y.; Dai, K.; Zhang, J.; Yan, M.; Zhang, Y. Genetic variant of WIF1 gene is functionally associated with developmental dysplasia of the hip in Han Chinese population. Sci. Rep. 2019, 9, 285. [Google Scholar] [CrossRef]
  35. Church, V.L.; Francis-West, P. Wnt signalling during limb development. Int. J. Dev. Biol. 2002, 46, 927–936. [Google Scholar] [PubMed]
  36. Chijimatsu, R.; Saito, T. Mechanisms of synovial joint and articular cartilage development. Cell Mol. Life Sci. 2019, 76, 3939–3952. [Google Scholar] [CrossRef] [PubMed]
  37. Zayzafoon, M. Calcium/calmodulin signaling controls osteoblast growth and differentiation. J. Cell Biochem. 2006, 97, 56–70. [Google Scholar] [CrossRef] [PubMed]
  38. Kajiya, H. Calcium signaling in osteoclast differentiation and bone resorption. Adv. Exp. Med. Biol. 2012, 740, 917–932. [Google Scholar]
  39. Duncan, R.L.; Akanbi, K.A.; Farach-Carson, M.C. Calcium signals and calcium channels in osteoblastic cells. Semin. Nephrol. 1998, 18, 178–190. [Google Scholar]
  40. Wu, M.; Wu, S.; Chen, W.; Li, Y.P. The roles and regulatory mechanisms of TGF-β and BMP signaling in bone and cartilage development, homeostasis and disease. Cell Res. 2024, 34, 101–123. [Google Scholar] [CrossRef]
  41. Kwon, H.-S.; Lee, H.-S.; Ji, Y.; Rubin, J.S.; Tomarev, S.I. Myocilin is a modulator of Wnt signaling. Mol. Cell Biol. 2009, 29, 2139–2154. [Google Scholar] [CrossRef] [PubMed]
  42. Atienzar-Aroca, R.; Aroca-Aguilar, J.-D.; Alexandre-Moreno, S.; Ferre-Fernández, J.-J.; Bonet-Fernández, J.-M.; Cabañero-Varela, M.-J.; Escribano, J. Knockout of myoc Provides Evidence for the Role of Myocilin in Zebrafish Sex Determination Associated with Wnt Signalling Downregulation. Biology 2021, 10, 188. [Google Scholar] [CrossRef] [PubMed]
  43. Catela, C.; Assimacopoulos, S.; Chen, Y.; Tsioras, K.; Feng, W.; Kratsios, P. The Iroquois (Iro/Irx) homeobox genes are conserved Hox targets involved in motor neuron development. iScience 2025, 28, 112210. [Google Scholar] [CrossRef] [PubMed]
  44. Janssens, S.; Denayer, T.; Deroo, T.; Van Roy, F.; Vleminckx, K. Direct control of Hoxd1 and Irx3 expression by Wnt/beta-catenin signaling during anteroposterior patterning of the neural axis in Xenopus. Int. J. Dev. Biol. 2010, 54, 1435–1442. [Google Scholar] [CrossRef]
  45. Liao, J.; Chen, B.; Zhu, Z.; Du, C.; Gao, S.; Zhao, G.; Zhao, P.; Wang, Y.; Wang, A.; Schwartz, Z.; et al. Long noncoding RNA (lncRNA) H19: An essential developmental regulator with expanding roles in cancer, stem cell differentiation, and metabolic diseases. Genes Dis. 2023, 10, 1351–1366. [Google Scholar] [CrossRef]
  46. Bassani, S.; Chrast, J.; Ambrosini, G.; Voisin, N.; Schütz, F.; Brusco, A.; Sirchia, F.; Turban, L.; Schubert, S.; Jamra, R.A.; et al. Variant-specific pathophysiological mechanisms of AFF3 differently influence transcriptome profiles. Genome Med. 2024, 16, 72. [Google Scholar] [CrossRef]
  47. Chen, J.-W.; Wang, Y.-X.; Gao, R.-R.; Ma, L.-Y.; Zhong, J.; Yang, J.-X.; Deng, Z.-H.; Li, Y.-Y.; Li, X.-L.; Shu, Y.-H.; et al. CDK14 regulates the development and repair of lung. Cell Death Discov. 2025, 11, 12. [Google Scholar] [CrossRef]
Figure 1. Distribution of transcripts shown as a volcano plot. Each point represents a gene. The red dots represent the differentially expressed genes (cutoff: |log2FC| > 2 (blue line), padj < 0.05).
Figure 1. Distribution of transcripts shown as a volcano plot. Each point represents a gene. The red dots represent the differentially expressed genes (cutoff: |log2FC| > 2 (blue line), padj < 0.05).
Ijms 26 08058 g001
Figure 2. PA plot from the transcripts. Each transcript is represented by a dot. The x-axis is the average expression over all samples, and the y-axis is the log2 fold change between the DDH and control groups.
Figure 2. PA plot from the transcripts. Each transcript is represented by a dot. The x-axis is the average expression over all samples, and the y-axis is the log2 fold change between the DDH and control groups.
Ijms 26 08058 g002
Figure 3. Top 10 enriched BP/MF/CC GO terms and KEGG pathways of DEGs between the DDH and control samples.
Figure 3. Top 10 enriched BP/MF/CC GO terms and KEGG pathways of DEGs between the DDH and control samples.
Ijms 26 08058 g003
Figure 4. Protein–protein interaction network analysis. The transcripts are grouped into 10 clusters. Each color represents one group.
Figure 4. Protein–protein interaction network analysis. The transcripts are grouped into 10 clusters. Each color represents one group.
Ijms 26 08058 g004
Table 1. Mapping percentages of the samples.
Table 1. Mapping percentages of the samples.
IDTreatmentMapping Rate (%)Read Number
(2 × 150 bp)
SRR14055716DDH80.7424,847,026
SRR14055717DDH84.9133,533,704
SRR14055718DDH80.8523,836,127
SRR14055719DDH98.2527,104,541
SRR14055720DDH87.7124,866,901
SRR14055721DDH94.2130,621,536
SRR14055722Control85.3523,421,990
SRR14055723Control93.5523,402,707
SRR14055724Control83.9925,453,109
SRR14055725Control83.4820,408,199
SRR14055726Control91.2225,169,198
SRR14055727Control90.2521,844,255
Table 2. Top 50 upregulated and downregulated differentially expressed genes between DDH and control samples.
Table 2. Top 50 upregulated and downregulated differentially expressed genes between DDH and control samples.
IDlog2 Fold Changep-ValueRegulation in DDH
ENSG00000034971−9.11.82 × 10−33Up
ENSG00000309097−7.60.011025698Up
ENSG00000256513−72.82 × 10−6Up
ENSG00000170549−6.57.46 × 10−9Up
ENSG00000250421−6.52.88 × 10−7Up
ENSG00000279096−6.41.67 × 10−5Up
ENSG00000306524−6.25.87 × 10−8Up
ENSG00000168447−5.91.51 × 10−14Up
ENSG00000240654−5.64.60 × 10−7Up
ENSG00000160097−5.53.54 × 10−9Up
ENSG00000286415−5.40.000715357Up
ENSG00000305982−5.40.007306598Up
ENSG00000305491−5.40.010014926Up
ENSG00000181408−5.32.18 × 10−9Up
ENSG00000179915−5.36.20 × 10−9Up
ENSG00000156076−5.31.73 × 10−5Up
ENSG00000271239−5.30.015421818Up
ENSG00000142973−5.27.44 × 10−12Up
ENSG00000214866−5.22.19 × 10−5Up
ENSG00000118733−5.20.000432547Up
ENSG00000274833−5.20.002264803Up
ENSG00000265962−5.20.004283014Up
ENSG00000301580−5.15.39 × 10−6Up
ENSG00000188803−5.12.66 × 10−5Up
ENSG00000305239−5.10.000191428Up
ENSG000002292366.51.94 × 10−6Down
ENSG000001876896.54.20 × 10−6Down
ENSG000001499686.61.96 × 10−14Down
ENSG000002666046.71.93 × 10−5Down
ENSG000001161476.70.002750078Down
ENSG000002119346.70.025736049Down
ENSG000002311316.89.52 × 10−11Down
ENSG000000128176.82.32 × 10−6Down
ENSG000002116606.80.023562957Down
ENSG000002493066.99.30 × 10−17Down
ENSG000002601976.91.98 × 10−7Down
ENSG0000022987671.05 × 10−6Down
ENSG0000018387874.61 × 10−6Down
ENSG000001143747.14.07 × 10−7Down
ENSG000000670487.22.85 × 10−14Down
ENSG000001265457.25.33 × 10−9Down
ENSG000001298247.33.60 × 10−8Down
ENSG000002315357.42.40 × 10−8Down
ENSG000002115987.54.07 × 10−7Down
ENSG000001652467.51.11 × 10−6Down
ENSG000002669957.76.79 × 10−14Down
ENSG000002910337.77.11 × 10−14Down
ENSG000000676467.91.88 × 10−13Down
ENSG000001377458.75.16 × 10−26Down
ENSG000001986929.48.86 × 10−7Down
Table 3. STRING k-means cluster descriptions.
Table 3. STRING k-means cluster descriptions.
Cluster NumberCluster ColorGene CountPrimary Description
1Red339Immune response
2Brown266Mitotic cell cycle process
3Dark goldenrod255Extracellular matrix
4Green-yellow133-
5Green 265-
6Green56-
7Blue53-
8Light sky blue41Postsynaptic cell membrane and protein–protein interactions at synapses
9Medium blue25ncRNAs involved in Wnt signaling in hepatocellular carcinoma, and regulation of FZD by ubiquitination
10Purple16O-linked glycosylation of mucins
Table 4. Top 100 upregulated and downregulated differentially expressed lncRNAs between DDH and control samples.
Table 4. Top 100 upregulated and downregulated differentially expressed lncRNAs between DDH and control samples.
IDBaseMeanLog2 Fold ChangelfcSEStatp-ValuepadjRegulation in DDH
ENSG0000030909720.0553182−7.63.00449956−2.54188330.01102570.12197728Up
ENSG0000025651312.8646141−71.49363454−4.68345692.82 × 10−60.00036368Up
ENSG0000025042113.1509542−6.51.2755177−5.13121262.88 × 10−76.37 × 10−5Up
ENSG000003065247.35762862−6.21.14212948−5.42274015.87 × 10−81.76 × 10−5Up
ENSG000002864154.37306511−5.41.6074669−3.38362470.000715360.02130454Up
ENSG000003059824.31991575−5.42.0210034−2.68253740.00730660.09516642Up
ENSG000003054914.18734128−5.42.08974346−2.57531350.010014930.1148278Up
ENSG0000027123912.0861402−5.32.17536921−2.42231870.015421820.1463899Up
ENSG000002748333.70182773−5.21.70130402−3.05311350.00226480.04671496Up
ENSG000002659623.6288218−5.21.81060089−2.85652860.004283010.07013193Up
ENSG000003015806.83679945−5.11.11596197−4.54909055.39 × 10−60.00057765Up
ENSG000003052396.90491206−5.11.36677843−3.73006810.000191430.00839207Up
ENSG000002338453.34256322−5.11.40746917−3.59169660.000328530.01242405Up
ENSG000003005023.29931021−51.71918577−2.93092250.003379570.06050065Up
ENSG0000029540412.0694117−52.17474927−2.28560730.022277250.18085266Up
ENSG000003070684.26292628−4.91.76580602−2.76218720.005741550.08279327Up
ENSG000002265622.83969294−4.82.15712697−2.23238780.025589340.19291473Up
ENSG0000026765318.6393025−4.61.18355532−3.88579920.000101990.00535485Up
ENSG000002986902.40410301−4.61.31131045−3.48161760.00049840.01688615Up
ENSG000003041633.60829109−4.61.63774551−2.82826870.004680050.07329761Up
ENSG000003004372.48886314−4.61.7087183−2.71032520.006721730.09071955Up
ENSG000002937572.45471648−4.62.2150069−2.08016950.037509990.23607729Up
ENSG000002856492.24907601−4.51.49009445−3.0066020.00264185NAUp
ENSG000002768312.26891435−4.52.15967333−2.0843450.03712879NAUp
ENSG000002242393.14919595−4.41.21015928−3.66943110.000243090.00996896Up
ENSG000002967192.07942702−4.41.29583942−3.37709640.00073255NAUp
ENSG000002956132.11341551−4.41.77626226−2.47221830.01342775NAUp
ENSG0000029807443.2261772−4.30.68673232−6.2275694.74 × 10−103.71 × 10−7Up
ENSG000002744783.94265842−4.31.38362988−3.07534080.002102620.04461646Up
ENSG000002274874.06682931−4.31.58140449−2.7216630.006495430.08932244Up
ENSG000002311321.92513856−4.31.86805998−2.27937490.02264479NAUp
ENSG000002960031.94909901−4.31.89990295−2.24850520.02454399NAUp
ENSG000002981931.92079493−4.31.96128058−2.168220.03014195NAUp
ENSG000002859361.97756865−4.32.1797068−1.96937650.04890988NAUp
ENSG000003002551.91034707−4.21.34504573−3.15803070.00158839NAUp
ENSG000002864681.92446954−4.21.69334955−2.50964690.0120852NAUp
ENSG000002974561.79753544−4.21.97057075−2.11025250.03483661NAUp
ENSG000002640072.74415058−4.22.02575856−2.09503470.03616790.23135695Up
ENSG0000023141910.5586343−4.10.95511704−4.27211841.94 × 10−50.00153673Up
ENSG000002971999.18829618−4.11.06625967−3.88981880.000100320.00528289Up
ENSG000003050112.48231308−4.11.18927314−3.45050290.000559540.01805428Up
ENSG000002294951.74392169−4.11.5299145−2.68667440.00721673NAUp
ENSG000002753583.47818747−4.11.70141215−2.40091390.016354180.15200984Up
ENSG000003009491.67487121−4.11.84983805−2.19632480.0280687NAUp
ENSG000002864112.505807−4.11.89232231−2.17424140.029687010.20751407Up
ENSG000002856863.5641727−4.11.91437549−2.15346630.031282050.21402918Up
ENSG000002868186.03882055−41.25554434−3.21550050.001302170.0325075Up
ENSG000002946281.600431−41.54122597−2.59090050.00957252NAUp
ENSG000003003973.36778179−41.71935962−2.34393410.019081550.1658802Up
ENSG000002349443.24048221−41.72676428−2.29282220.021858240.1789809Up
ENSG000002049713.449933535.41.397937873.846191670.000119970.00603911Down
ENSG000002982683.465100395.41.486405563.604638080.000312590.01198425Down
ENSG000002581834.833472545.41.566606743.415226490.000637290.01970541Down
ENSG0000030338967.44912125.41.599609873.390169590.000698490.02101712Down
ENSG000002496673.572323755.41.788799453.025703120.002480560.04947514Down
ENSG000002499933.518279415.41.817141312.963818340.003038480.05650863Down
ENSG000003100623.485781395.41.83016542.934390460.003342040.06010549Down
ENSG000003041113.543459375.41.855459232.906636330.003653380.06364457Down
ENSG000003083993.523722085.42.066508392.608442940.009095520.10839416Down
ENSG000002906703.523991925.42.089025772.579827230.009884980.1137742Down
ENSG000003006403.539140295.42.126853732.536470220.011197630.12259215Down
ENSG000003061643.457928795.42.152006162.491733120.012712150.13155437Down
ENSG000002508223.600907735.42.480730632.185924090.028821160.20492453Down
ENSG000002908405.178884455.51.508035763.618586370.000296220.01151552Down
ENSG000003009473.785761145.51.639015923.347446410.00081560.02356484Down
ENSG000002897073.825743075.51.733527723.183305330.001456040.03503209Down
ENSG000003005653.739790545.51.76816753.098581230.00194450.04225892Down
ENSG000002503483.816187285.52.450022862.25185870.02433120.1891298Down
ENSG00000230838194.5014235.60.705771567.987938171.37 × 10−153.81 × 10−12Down
ENSG0000029876822.83228695.60.957377915.855993234.74 × 10−92.68 × 10−6Down
ENSG000002240994.193134835.61.772490833.181138460.001466980.03521975Down
ENSG000003085135.85019615.61.888103882.978283920.002898670.05482292Down
ENSG000002950564.326120765.71.363495584.182521972.88 × 10−50.00207142Down
ENSG000002599378.834253975.71.449771423.952828577.72 × 10−50.00441933Down
ENSG000002880154.276789365.71.462196993.872826950.000107580.00555274Down
ENSG000003087314.337539565.71.552326523.665615130.000246750.01005271Down
ENSG000002880494.246906625.71.694217823.349571010.000809370.02348628Down
ENSG000002535544.331061585.71.75073663.248466260.001160290.03006132Down
ENSG000002325966.403575775.81.514020823.799134740.00014520.00686811Down
ENSG000002980494.645461885.81.771703433.266036660.001090640.02881119Down
ENSG0000029422217.69144365.91.477710164.018988155.84 × 10−50.00358626Down
ENSG00000293442155.3697995.91.486394663.935702698.30 × 10−50.00466193Down
ENSG000002649855.197242865.91.567864433.792141010.000149350.00698876Down
ENSG000002945085.072967985.91.756834383.367305020.000759070.02236649Down
ENSG000002516705.2753203861.256704544.74549572.08 × 10−60.00029154Down
ENSG000002338545.743686196.11.309389434.651134083.30 × 10−60.0004047Down
ENSG000002860285.904429626.11.456596434.210374162.55 × 10−50.00189082Down
ENSG0000029883932.29898966.21.038854175.940966162.83 × 10−91.80 × 10−6Down
ENSG0000029304712.28177876.21.114897625.572386672.51 × 10−88.72 × 10−6Down
ENSG000002493438.407986776.21.552875933.961574437.45 × 10−50.00429032Down
ENSG0000017672857.98918646.51.113091515.797567856.73 × 10−93.12 × 10−6Down
ENSG0000027121615.25944456.51.368375524.775293731.79 × 10−60.0002611Down
ENSG0000022923610.33495286.51.357691074.759965511.94 × 10−60.00027647Down
ENSG000002666048.704114746.71.566812294.272807491.93 × 10−50.00153597Down
ENSG0000023113118.92611876.81.057598336.474363379.52 × 10−118.31 × 10−8Down
ENSG00000249306151.6200516.90.828754068.31335389.30 × 10−174.06 × 10−13Down
ENSG0000026019719.73483456.91.329449215.201308591.98 × 10−74.72 × 10−5Down
ENSG0000022987610.521378571.427084184.882368941.05 × 10−60.00017407Down
ENSG0000023153527.07975067.41.321580655.580078932.40 × 10−88.44 × 10−6Down
ENSG00000291033276.1251487.71.032275357.485813797.11 × 10−141.21 × 10−10Down
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Kaya, İ.; Türktaş, M.; Yaş, S.; Bircan, R. Genome-Wide mRNA and lncRNA Expression Profiling to Uncover Their Role in the Molecular Pathogenesis of Developmental Dysplasia of the Hip. Int. J. Mol. Sci. 2025, 26, 8058. https://doi.org/10.3390/ijms26168058

AMA Style

Kaya İ, Türktaş M, Yaş S, Bircan R. Genome-Wide mRNA and lncRNA Expression Profiling to Uncover Their Role in the Molecular Pathogenesis of Developmental Dysplasia of the Hip. International Journal of Molecular Sciences. 2025; 26(16):8058. https://doi.org/10.3390/ijms26168058

Chicago/Turabian Style

Kaya, İbrahim, Mine Türktaş, Semih Yaş, and Resul Bircan. 2025. "Genome-Wide mRNA and lncRNA Expression Profiling to Uncover Their Role in the Molecular Pathogenesis of Developmental Dysplasia of the Hip" International Journal of Molecular Sciences 26, no. 16: 8058. https://doi.org/10.3390/ijms26168058

APA Style

Kaya, İ., Türktaş, M., Yaş, S., & Bircan, R. (2025). Genome-Wide mRNA and lncRNA Expression Profiling to Uncover Their Role in the Molecular Pathogenesis of Developmental Dysplasia of the Hip. International Journal of Molecular Sciences, 26(16), 8058. https://doi.org/10.3390/ijms26168058

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop